GSKGlaxoSmithKlineSigning up patients
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Sarcoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 64 (planned)
- Started
- Jun 22, 2026
- Main results expected
- Nov 5, 2027
- Fully finished
- Nov 23, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Progression free survival rate at Week18 (PFS18)
Measured over: At Week 18
Cohort 1 & 2: Confirmed Objective Response Rate (ORR)
Measured over: Up to approximately 98 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07602777 · record last updated 2026-10-01 · checked 2026-11-09 15:47 UTC